ECSP13013073A - Derivados de benzamida sustituida - Google Patents
Derivados de benzamida sustituidaInfo
- Publication number
- ECSP13013073A ECSP13013073A ECSP13013073A ECSP13013073A EC SP13013073 A ECSP13013073 A EC SP13013073A EC SP13013073 A ECSP13013073 A EC SP13013073A EC SP13013073 A ECSP13013073 A EC SP13013073A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- halogen
- lower alkyl
- pyridin
- trifluoromethyl
- Prior art date
Links
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- -1 2,2-difluorbenzo [d] [1,3] dioxol-5-yl Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000009045 body homeostasis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmulaen la que:R1 es hidrógeno, halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno o C(O)NH2,o es fenilo opcionalmente sustituido por halógeno, ciano o alcoxi inferior sustituido por halógeno, o es 2,2-difluorbenzo[d][1,3]dioxol-5-ilo, o es 6-(trifluormetil)-pirazin-2-ilo o 5-(trifluormetil)pirazin-2-ilo o es 6-(trifluormetil)pirimidin-4-ilo, o es 6-(trifluormetil)-piridin-3-ilo, o es 5-cianopirazin-2-ilo o es 2-(tri-fluormetil)pirimidin-4-ilo;n es el número 1 ó 2R2 es halógeno, alquilo inferior o ciano y R3 es hidrógeno, oR2 es hidrógeno y R3 es halógeno, alquilo inferior o ciano;X es un enlace, -NR'-, -CH2NH- o -CHR'-;R' es hidrógeno o alquilo inferior; Z es un enlace, -CH2- u -O-;Ar es fenilo o es heteroarilo elegido entre el grupo formado por 1H-indazol-3-ilo, piridin-2-ilo, piridin-3-ilo, piridin-4-ilo, pirimidin-5-ilo, 1H-pirazol-3-ilo, 1H-pirazol-4-ilo y 1H-pirazol-5-ilo;o una sal de adición de ácido farmacéuticamente apropiada de los mismos; que pueden utilizarse para el tratamiento de la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, los trastornos psicóticos, la esquizofrenia, las enfermedades neurológicas, la enfermedad de Parkinson, los trastornos neurodegenerativos, la enfermedad de Alzheimer, la epilepsia, la migraña, la hipertensión, el abuso de sustancias, los trastornos metabólicos, los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y malfunción de la homeostasis de la temperatura corporal, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169441 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13013073A true ECSP13013073A (es) | 2014-01-31 |
Family
ID=46298391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13013073 ECSP13013073A (es) | 2011-06-10 | 2013-12-10 | Derivados de benzamida sustituida |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9029370B2 (es) |
| EP (1) | EP2718271B1 (es) |
| JP (1) | JP5788087B2 (es) |
| KR (1) | KR101574906B1 (es) |
| CN (1) | CN103596937B (es) |
| AR (1) | AR086880A1 (es) |
| AU (1) | AU2012266462B2 (es) |
| BR (1) | BR112013030698B1 (es) |
| CA (1) | CA2834675C (es) |
| CL (1) | CL2013003485A1 (es) |
| CO (1) | CO6811866A2 (es) |
| CY (1) | CY1116769T1 (es) |
| DK (1) | DK2718271T3 (es) |
| EA (1) | EA022376B1 (es) |
| EC (1) | ECSP13013073A (es) |
| ES (1) | ES2546529T3 (es) |
| HR (1) | HRP20151201T1 (es) |
| IL (1) | IL229335A (es) |
| MA (1) | MA35194B1 (es) |
| MX (1) | MX354410B (es) |
| MY (1) | MY162461A (es) |
| PE (1) | PE20140968A1 (es) |
| PH (1) | PH12013502263A1 (es) |
| PL (1) | PL2718271T3 (es) |
| PT (1) | PT2718271E (es) |
| RS (1) | RS54415B1 (es) |
| SG (1) | SG194840A1 (es) |
| SI (1) | SI2718271T1 (es) |
| TW (1) | TWI445701B (es) |
| UA (1) | UA110388C2 (es) |
| WO (1) | WO2012168265A1 (es) |
| ZA (1) | ZA201308401B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| RU2621050C2 (ru) * | 2012-01-12 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars) |
| NO2895477T3 (es) * | 2012-09-14 | 2018-03-31 | ||
| CA2879176C (en) * | 2012-09-17 | 2020-10-27 | F.Hoffmann-La Roche Ag | Triazole carboxamide derivatives |
| BR112015009990A2 (pt) * | 2012-11-07 | 2017-07-11 | Hoffmann La Roche | derivados de pirazina |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| WO2015181061A1 (en) * | 2014-05-28 | 2015-12-03 | F. Hoffmann-La Roche Ag | 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators |
| CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
| JP6814814B2 (ja) | 2016-03-17 | 2021-01-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体 |
| CA3146830A1 (en) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| CN115515940A (zh) * | 2020-02-28 | 2022-12-23 | 德州大学系统董事会 | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 |
| TW202440563A (zh) * | 2022-11-28 | 2024-10-16 | 美商住友製藥美國公司 | 2-苯基嗎啉與2-苯基(硫代)嗎啉化合物及其用途 |
| WO2025165774A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| WO2025165773A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| PT1036065E (pt) | 1997-12-04 | 2004-09-30 | Allergan Inc | Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| BRPI0806932A2 (pt) * | 2007-02-02 | 2014-05-06 | Novartis Ag | Antagonista do receptor s1p1 de cromeno |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| CN101765425A (zh) | 2007-08-02 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 苯甲酰胺衍生物用于治疗cns障碍的用途 |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| CA2771822C (en) | 2009-09-04 | 2020-08-11 | Daniel A. Erlanson | Bruton's tyrosine kinase inhibitors |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
-
2012
- 2012-06-01 US US13/485,993 patent/US9029370B2/en active Active
- 2012-06-06 SG SG2013082656A patent/SG194840A1/en unknown
- 2012-06-06 KR KR1020147000701A patent/KR101574906B1/ko not_active Expired - Fee Related
- 2012-06-06 WO PCT/EP2012/060637 patent/WO2012168265A1/en not_active Ceased
- 2012-06-06 AU AU2012266462A patent/AU2012266462B2/en not_active Ceased
- 2012-06-06 PL PL12727633T patent/PL2718271T3/pl unknown
- 2012-06-06 MX MX2013014371A patent/MX354410B/es active IP Right Grant
- 2012-06-06 CN CN201280028534.4A patent/CN103596937B/zh not_active Expired - Fee Related
- 2012-06-06 RS RS20150747A patent/RS54415B1/sr unknown
- 2012-06-06 EP EP12727633.5A patent/EP2718271B1/en active Active
- 2012-06-06 ES ES12727633.5T patent/ES2546529T3/es active Active
- 2012-06-06 DK DK12727633.5T patent/DK2718271T3/en active
- 2012-06-06 MY MYPI2013003963A patent/MY162461A/en unknown
- 2012-06-06 PE PE2013002778A patent/PE20140968A1/es active IP Right Grant
- 2012-06-06 PH PH1/2013/502263A patent/PH12013502263A1/en unknown
- 2012-06-06 PT PT127276335T patent/PT2718271E/pt unknown
- 2012-06-06 SI SI201230320T patent/SI2718271T1/sl unknown
- 2012-06-06 JP JP2014514044A patent/JP5788087B2/ja not_active Expired - Fee Related
- 2012-06-06 CA CA2834675A patent/CA2834675C/en active Active
- 2012-06-06 HR HRP20151201TT patent/HRP20151201T1/hr unknown
- 2012-06-06 UA UAA201400121A patent/UA110388C2/ru unknown
- 2012-06-06 EA EA201391815A patent/EA022376B1/ru not_active IP Right Cessation
- 2012-06-06 BR BR112013030698-0A patent/BR112013030698B1/pt not_active IP Right Cessation
- 2012-06-07 TW TW101120551A patent/TWI445701B/zh not_active IP Right Cessation
- 2012-06-08 AR ARP120102045A patent/AR086880A1/es unknown
-
2013
- 2013-11-07 ZA ZA2013/08401A patent/ZA201308401B/en unknown
- 2013-11-07 IL IL229335A patent/IL229335A/en active IP Right Grant
- 2013-11-29 CO CO13281375A patent/CO6811866A2/es active IP Right Grant
- 2013-12-05 CL CL2013003485A patent/CL2013003485A1/es unknown
- 2013-12-10 EC ECSP13013073 patent/ECSP13013073A/es unknown
- 2013-12-18 MA MA36585A patent/MA35194B1/fr unknown
-
2015
- 2015-10-06 CY CY20151100894T patent/CY1116769T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013073A (es) | Derivados de benzamida sustituida | |
| AR085478A1 (es) | Derivados heterociclicos de amina | |
| AR088741A1 (es) | Derivados de pirazol | |
| CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| MX378486B (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| CO6331336A2 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| BR112014015832A2 (pt) | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) | |
| MX2015001108A (es) | Derivados de triazol carboxamida. | |
| AR063326A1 (es) | Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central | |
| PH12015500489B1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease | |
| AR101339A1 (es) | Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo | |
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
| SI3149002T1 (en) | 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators | |
| TH146321A (th) | อนุพันธ์ของเบนซาไมด์ที่ถูกแทนที่ | |
| RU2017106928A (ru) | Замещенные производные пиразино[2,1-а]изохинолина для лечения заболеваний цнс |